Bipartisan health committee members reject limits on syringe service programs
A sharps disposal box sits beside Needlepoint Sancutary's set up at Camp Hope, an unhoused encampment in Bangor. The syringe service program hands out provisions and clean syringes along with kits containing fentanyl testing strips and the overdose reversal drug Naloxone. (Photo by Eesha Pendharkar/Maine Morning Star)
A majority of legislators on the health committee on Wednesday rejected a bill to limit the number of clean syringes certified programs can hand out, backing Maine's more flexible policy, which medical providers and harm reduction experts have vouched for.
Penobscot County is currently experiencing an HIV outbreak, with 22 cases since last October (compared to one or two cases a year, in recent years). During the public hearing on the bill, health providers and operators of syringe service programs stressed the importance of access to clean needles in the light of this outbreak, citing research that supports the efficacy of these programs.
But some municipalities have blamed expanded syringe services for syringe litter on sidewalks, public parks and private property.
LD 216, introduced by Rep. Anne-Marie Mastraccio (D-Sanford), would limit the number of clean syringes needle exchanges can hand out, reverting to a one-for-one ratio that Maine allowed until 2022, before adopting new rules that allow participants to bring in just one used syringe to receive 100 clean ones. Maine Department of Health and Human Services also allows participants to receive up to 100 syringes, even if they don't bring any used ones in, at the discretion of the provider.
Maine DHHS, which oversees the Maine Center for Disease Control and Prevention, opposed the bill, arguing the 'proposed language is not supported by evidenced based practice, would limit access, and increases infectious disease transmission risk including HIV and Hepatitis C,' according to testimony by Maine CDC Director Dr. Puthiery Va.
Needle exchanges face municipal pushback despite state, public health backing
Both Republicans and Democrats on the Legislature's Health and Human Services Committee said Wednesday that municipalities should decide what policies are best suited for needle exchanges in their communities, but the statewide ratio does not need to change.
'To me, it just sounds like a disposal issue,' Sen. Marianne Moore (R-Washington) said during the work session on the bill. 'However, it's local control, so each of the cities can do their own ordinance. So I personally think that we should just leave it up at 100, because it's been working other than the disposal part of it.'
With the exception of a few votes, the vast majority of the health committee voted against Mastraccio's bill. That recommendation now heads to the full House and Senate to consider.
Last November, Sanford passed an emergency ordinance to revert back to the one-for-one syringe ratio, which Mastraccio said appears to have reduced syringe litter.
'We believe the ordinance has reduced the number of discards greatly, and I have not heard of corresponding outbreaks of HIV or Hepatitis among the needle exchange population,' she said in public testimony.
Amanda Campbell of the Maine Municipal Association also said many towns and cities supported the tighter restrictions on needle exchanges because they are 'concerned about the safety of their public works employees and their residents who are consistently exposed to used needle litter.'
But according to the Maine CDC's syringe service report from 2023, released last May, most users bring in roughly the same amount of syringes they receive. Syringe services handed out 1.16 syringes for each one they collected last year, which means that despite some concern about the state's 100 to 1 ratio, the effective rate of exchange has not dramatically changed.
Syringe service programs also provide sharps disposal containers and help reduce discarded waste in communities, according to Dr. Kinna Thakarar, a physician at Maine Medical Center and an associate professor at the Tufts University School of Medicine.
Another solution lawmakers discussed is Portland's needle buyback program, which the city's public health director, Bridget Rauscher, said has helped reduce syringe litter by 76% and also resulted in a 58% increase in used syringe return. Participants can earn 10 cents per used needle they turn in, with a weekly cap of 200 syringes per person.
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
28 minutes ago
- The Hill
House GOP advances first 2026 funding bill out of committee
House Republicans early Wednesday morning advanced legislation that calls for more than $450 billion to fund the Department of Veterans Affairs, military construction and other programs for fiscal year 2026. The bill advanced out of the GOP-led House Appropriations Committee along party lines, as Democrats came out in strong opposition to the plan. It marks the first of the 12 annual funding bills House GOP appropriators are hoping to move out of committee before Congress leaves for its August recess. The bill calls for about $152 billion in discretionary funding for fiscal 2026, marking a 3 percent increase compared to current levels. Overall, the bill would provide about $453 billion for the VA, including $300 billion for mandatory programs. Among the increases Republicans have highlighted in the measure are boosts to the VA, military construction and family housing, and funding for a new homelessness program. In his opening remarks on Tuesday, Rep. John Carter (R-Texas), the head of the subcommittee that crafts the annual funding bill, said the bill ensures 'veterans get the benefits and care they've earned.' 'The bill does that while also addressing other issues affecting veterans, including homelessness, mental health services and taking care of our women veterans,' he said. 'The bill also makes crucial investments totaling nearly $18 billion in the infrastructure of our service members need to work on to live.' Democrats, however, have railed against the plan, needling Republicans for not including advanced funding for the Toxic Exposure Fund in the proposal, which they also said falls nearly $1 billion short of the funding needed for military construction. Democrats have also accused Republicans of seeking to privatize medical care for veterans. 'This bill hurdles us towards VA privatization, a top project 2025, priority that undercuts what veterans consistently ask for, which is the high quality medical care at VA, by transferring record funding from VA medical services to community care,' Rep. Debbie Wasserman Schultz (Fla.), the top Democrat on the veterans' funding subcommittee, said. House Appropriations Chair Tom Cole (R-Okla.) has emphasized as the committee ramps up its funding work that the legislation currently being considered will look different when eventual bipartisan spending talks begin. Senior GOP appropriators have also acknowledged that further changes are possible during the annual process as they await more information from the Trump administration about the president's vision for government funding for fiscal 2026 and beyond. 'As this process moves forward and we receive further documentation on the OMB budget, we will take it under consideration, put forward a product that best addresses the needs of our service members and veterans,' Carter said during the meeting on Tuesday, referring to the Office of Management and Budget. The bill comes about a week after hardline conservatives urged top appropriators to write bills 'consistent' with President Trump's budget request and to 'include adjustments initiated' by his Department of Government Efficiency. In a slim budget request released earlier this year, Trump called for cutting funding for domestic programs by more than $160 billion for fiscal 2026. As appropriators await more details from the administration, the committee also approved interim subcommittee allocations for a third of the annual funding bills. 'These interim allocations will allow us to begin our work. As we move forward, this committee is prepared to do the hard work – line by line – to uphold fiscal discipline and effective governance,' Cole said. However, Rep. Rosa DeLauro (Conn.), the top Democrat on the House Appropriations Committee, criticized Republicans over the process, saying negotiators are 'beginning the appropriations process without a total funding level.' 'We are flying blind and handcuffed into the critical work of providing discretionary funding for programs and services across the government that help to grow the middle class, protect the working class, support small businesses, and grow our economy – this is important business that cannot be done responsibly without a complete vision for how we plan to fund the government.'
Yahoo
an hour ago
- Yahoo
With Rick Perry's backing and $50 million from the state, Texas set to become a leader in psychedelics research
As Texas sets to crack down on the recreational use of cannabis, state leaders are opting to invest $50 million in another plant with purported medicinal benefits – a psychedelic called ibogaine. For several years, people have silently traveled to clinics in Mexico to take ibogaine. The extract of an ancient African shrub has been used across the Texas border to alleviate addiction and brain trauma. Texas Gov. Greg Abbott is set to sign Senate Bill 2308 on Wednesday, creating a consortium of universities, hospitals, and drug developers to conduct clinical trials on an ibogaine drug, with the hopes of receiving U.S. Food and Drug Administration approval. Lawmakers approved $50 million in taxpayer dollars to support this effort, making Texas the global leader in psychedelic research investment. Since Texas is trying to be the first to develop the drug, the legislation ensures Texas retains control of the research and development process. The goal of this investment is to ensure Texans reap the economic benefits from an ibogaine treatment program, not a pharmaceutical company. The investment entitles Texas to at least 20% of any successful ibogaine drug resulting from the trials, with a quarter of that revenue allocated to a fund for state veterans. After a failed attempt in Kentucky to start a state-funded ibogaine drug, Texas has picked up the effort under the leadership of a familiar statewide figure-turned psychedelics cheerleader — former Gov. Rick Perry. 'None of this is possible without Perry,' said Bryan Hubbard, the former chair of the Kentucky Opioid Abatement Advisory Commission and current executive director of the American Ibogaine Initiative. 'He made it happen in Texas. That is a big deal and catches the attention of the nation.' Ibogaine is an illegal drug that has found itself in a unique position where Republicans champion it. This comes as some of them, led by Lt. Gov. Dan Patrick, have made it a mission this session to ban recreational use of THC, which awaits Abbott's approval. Katharine Neill Harris, a drug policy fellow at Rice University's Baker Institute for Public Policy, said it's easy for Republicans to sign on to ibogaine because the intent of it is to medicinally treat addiction. 'Also, this bill doesn't grant public access to ibogaine, and there's nothing in the bill that could really be construed as soft on drugs,' she said. For that reason seemingly, Patrick has publicly thrown his support toward ibogaine as he fends off critics from the left and right for his hardline views on THC. Patrick did not respond to a request for a comment for this story. Harris said Texas' investment in ibogaine could kickstart a trend across states to invest in drug research to address addiction, as private funds have become inconsistent. 'In 2024, the FDA rejected a proposal to approve MDMA-assisted therapy for PTSD. MDMA-assisted therapy for PTSD is one of the more studied alternative psychedelic treatment protocols, and the FDA rejection was a huge blow to private industry, likely leading some to rethink investment in this area,' she said. It was early 2022, and the only thing former Army Ranger Chase Rowan could think about was killing himself. Sixteen years prior, his parachute failed to fully deploy during a nighttime training exercise as his body careened toward the ground at 60 miles per hour. To cope through the pain from the severe brain injury that resulted, the Lubbock resident turned to opioids which morphed into a fentanyl addiction that eventually dissolved his family. 'I was stuck alone. I had no money and no vehicle, just white knuckling sobriety,' Rowan said. When Rowan got to Mexico to test out a novel drug called ibogaine in August of 2022, he wasn't scared, but determined to heal. Upon taking the ibogaine pill, Rowan started seeing images — one of a devil with wings and another of roads leading to childhood memories. The psychedelic journey on his first night opened his eyes to past trauma and the pain he caused to those around him, like a movie. He woke up the next day feeling the happiest he had been in 20 years. 'It felt like a weight was lifted off of me,' he said. 'I got that stuff out of me.' What Rowan was dealing with is a particular high that comes from ibogaine that is often referred to as a 'spiritual awakening' or a greater sense of self. Stanford Medicine conducted a study in 2024 that found 'ibogaine, when combined with magnesium to protect the heart, safely and effectively reduces PTSD, anxiety and depression and improves functioning in veterans with' traumatic brain injury. Hubbard sees no threat of ibogaine becoming recreationally used or abused since it does not provide an enjoyable high and leaves the user in a state of temporary paralysis. Because of this, most never go back for another dose. 'There is no street economy for this drug,' Hubbard said. Ibogaine also comes with potential dangers. Harris calls it one of the 'more complicated psychedelics to administer' because it brings risks of cardiac issues and sudden death. The risks make it more expensive to study and to provide as a treatment, drawing out the years that ibogaine becomes more widely available, Harris said. 'If the FDA were to approve ibogaine for opioid use disorders or other disorders…the treatment could be quite costly,' Harris said. Since leaving his two-year stint as U.S. Energy Secretary during the first Trump administration, Perry has thrown the weight of his reputation behind psychedelics, becoming one of the most high-profile advocates of its research nationally. But the journey to this point started when he still occupied the Governor's Mansion in Austin. 'It's the question I hear the most,' Perry said with a laugh. 'What is a right-wing anti-drug governor doing associated with psychedelics?' In 2006, Perry became close with Navy SEAL veteran Marcus Luttrell who struggled from a brain injury, PTSD and addiction, without access to effective treatments. He recalls Luttrell sleeping with the TV and lights on, trying to comfort his battered mind. When Luttrell told him he was planning to go to Mexico with several other veterans to try ibogaine, Perry was skeptical. 'I remember the first time he told me, and I looked at him the same way a dog does when they hear a funny noise. I remember telling him to be careful with that because I still had my beliefs on drugs at the time, but at the same time, people that I trusted were going to Mexico for this, I had to listen,' Perry said. The data was indisputable to Perry. He unequivocally believes ibogaine takes away addiction and he is ready to tell anyone who will ask him about it. He has since gone on to the Joe Rogan podcast to wax poetic about the drug and other psychedelic treatments. He is a scheduled speaker for a psychedelic conference in Denver. He is also planning to reach out to officials in Israel and Ukraine to initiate ibogaine treatment programs there. 'I have always been open to new knowledge. The same thing with criminal justice reform and in-state tuition, as a Republican, I have my beliefs, but I am willing to change them once looking at the data and science,' Perry said. Hubbard cautioned that ibogaine is not a drug to be taken without medical supervision and Texas is probably at least six years away from seeing any movement on FDA approval for clinical trials. However, he is hopeful that the drug qualifies for a Breakthrough Therapy designation, a pathway that accelerates the regulatory review of drugs showing early promise in treating severe conditions. As of June 30, 2024, the FDA has only granted 587 designations out of the 1,516 requested since 2012. Hubbard believes the current presidential administration will see the momentum in Texas and help expedite the process with the FDA. 'If Texas can create a treatment plan for ibogaine, it might be the most significant achievement in modern medicine for nearly a century,' said Hubbard. Disclosure: Rice University and Rice University's Baker Institute for Public Policy have been financial supporters of The Texas Tribune, a nonprofit, nonpartisan news organization that is funded in part by donations from members, foundations and corporate sponsors. Financial supporters play no role in the Tribune's journalism. Find a complete list of them here. Big news: 20 more speakers join the TribFest lineup! New additions include Margaret Spellings, former U.S. secretary of education and CEO of the Bipartisan Policy Center; Michael Curry, former presiding bishop and primate of The Episcopal Church; Beto O'Rourke, former U.S. Representative, D-El Paso; Joe Lonsdale, entrepreneur, founder and managing partner at 8VC; and Katie Phang, journalist and trial lawyer. Get tickets. TribFest 2025 is presented by JPMorganChase.
Yahoo
2 hours ago
- Yahoo
Most voters in favor of Trump's ‘most favored nation' drug price policy: survey
A new survey found that a majority of voters are in favor lawmakers and candidates who they believe will take on Big Pharma price-gouging with most saying they're in favor of President Trump's 'most favored nation' policy. In a survey commissioned by the Pharmaceutical Reform Alliance and conducted by National Research Inc., 85 percent of voters said prescription medications have gotten more expensive and nearly the same percentage of participants said pharmaceutical companies carried the most blame for the high cost. When asked about their voting choices, 86 percent said they were more likely to support a candidate who 'wants to force Big Pharma to lower prescription medication costs for American consumers' while 78 percent said they were less likely to support a candidate who accepted donations from Big Pharma. Overall, 90 percent of participants agreed with this statement: 'Congressional candidates should stop taking large political donations from Big Pharma because it is a conflict of interest.' During the 2024 election cycle, pharmaceutical and health product political action committees donated over $16 million to campaigns. 'Americans are speaking loudly and clearly, so it's important for Congress to listen: the time to join President Trump in lowering prescription drug costs is NOW. From coast to coast, the American people are suffering from high prescription costs, and they rightly blame Big Pharma. Simply stated, it's time for Big Pharma to put America first…not last,' PRA spokesman and former Rep. J.D. Hayworth (R-Ariz.) said in a statement. 'No doubt those currently serving on Capitol Hill are hearing the same message from their constituents. With the 2026 primary season ahead, those in the House and Senate need to take action. Voters are watching,' he added. The survey highlighted Trump's executive order that enacted 'most favored nation' drug pricing as an example of efforts to reduce prescription drug costs. The executive order directs the Department of Commerce and the U.S. Trade Representative Jamieson Greer to take 'all appropriate action' against 'unreasonable and discriminatory' policies in foreign countries that suppress drug prices abroad. Health and Human Services Secretary Robert F. Kennedy Jr. will set 'clear targets' for prescription drug and pharmaceutical price reductions within 30 days per the order. When asked about how they felt regarding the 'most favored nation' policy, 78 percent said they supported the policy, which included 61 percent of Democrats, 77 percent of independent voters and 96 percent of Republicans. Republican participants were asked to pick between Trump; Kennedy and his 'make American health again' agenda; or Congress when it came to whom they trusted to 'force Big Pharma to lower their costs for prescription medicine.' Trump received the highest vote of confidence with 46 percent of GOP voters picking him, 14 percent picked Kennedy and only two percent picked Congress. Other changes that garnered support in the survey were restrictions on direct-to-consumer prescription medication ads and 78 percent agreed it was a conflict of interest for news networks to run such ads as they're covering health care issues. The survey was conducted from May 28 to June 1 and included 1,000 registered voters. The results have a margin or error of plus or minus 3.1 percentage points at the 95 percent confidence interval. Among participants, 35 percent were Republican, 33 percent were Democrat and 32 percent were independent. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
